best marijuana stocks to buy

canada - search results

If you're not happy with the results, please do another search

0 835

Bedrocan receives Health Canada MMPR Production License

Import Permit Issued for Transfer of Genetic Clones from the Netherlands

TORONTO , Feb. 19, 2015 /CNW/ – Bedrocan Cannabis Corp. (BED.V) (“Bedrocan” or the “Company”) announced today that its wholly-owned subsidiary, Bedrocan Canada Inc., has received a second license from Health Canada to allow for the production of medicinal cannabis under the Marihuana for Medicinal Purposes Regulations (“MMPR”). Under the terms of this license, which became effective on February 17, 2015 for a period of one year, Bedrocan can immediately begin domestic production in the first six grow rooms, out of a total of 34, at the Company’s new 52,000 square foot production facility in the Greater Toronto Area . When fully licensed by Health Canada, the facility is capable of producing approximately 4,000 kg of medicinal cannabis per year.

Bedrocan now has two licensed facilities in operation in the Greater Toronto Area . As previously announced on December 3, 2014 , Bedrocan also has an existing Health Canada license, which was renewed for an additional one year term expiring on December 2, 2015 , to import up to 240 kg from the Dutch government’s Office of Medicinal Cannabis. The Company will now begin the transition to full domestic production, constituting Phase II of the Company’s growth strategy.

Furthermore, Health Canada has also issued Bedrocan an import permit to allow for immediate transfer of live genetic clones from Bedrocan BV in the Netherlands to the Company’s domestic production facility. Bedrocan’s import permit from Health Canada follows the issuance of an additional import permit from the Canadian Food Inspection Agency, allowing for the first ever legal import of live cannabis plants into Canada

“We are delighted to have reached this critical milestone in our growth strategy, allowing us to significantly scale up the volume of product we can offer to Canadian patients,” said Marc Wayne , President and CEO. “We remain on schedule to deliver our first production harvest and sale in Q2’2015. In addition, our import strategy will remain in place through transition to full domestic production to ensure a continued, consistent and uninterrupted supply of medicinal cannabis to our patients.”

Bedrocan is the only company in the world capable of offering patients standardized full-bud dried cannabis, containing consistent levels of cannabinoids (the active ingredients) from batch to batch. Product standardization is the only way to  provide physicians and patients with consistency and replicability of therapeutic effect, and thereby enhanced ability to track efficacy, safety and side effects over time. Production at the new domestic facility will be grown from clones that are genetically identical to those developed by Bedrocan BV.

About Bedrocan

Bedrocan and Bedrocan BV are focused on medicinal cannabis research and product innovation, and have been producing and supplying government-regulated medicinal cannabis for 13 years. Bedrocan’s strains of pharmaceutical-grade cannabis have been used by more than 20,000 patients in seven countries, including Canada . The Company is committed to clinical research with ISO 9001-rated production processes and product development, on an international scale. Bedrocan is one of only two companies currently supplying pharmaceutical-grade medicinal cannabis in Canada . Bedrocan Cannabis Corp. trades on the TSX Venture Exchange under the symbol “BED”.

Forward-Looking Statements

Certain information in this release are forward-looking statements with respect to the development plans and growth targets of the Company. Forward-looking statements consist of statements that are not purely historical, including statements regarding beliefs, plans, expectations or intensions for the future, and include, but not limited to, statements with respect to: (a) the commencement of domestic production of medicinal cannabis by the Company, and capacity for such production; (b) the Company’s plan to scale up the volume of its product available to Canadian patients; and (c) the success of the Company’s import and domestic production strategy.  The basis for the assumptions underlying such statements include that: (i) Bedrocan’s existing licenses will remain in full force and effect, and be renewed upon terms acceptable to Bedrocan in the future; (ii) actual results of the Company’s planned domestic production and development activities will continue to be positive and proceed as planned; (iii) all requisite regulatory and governmental approvals will be received on a timely basis on terms acceptable to the Company, and (iv) economic, political and industry market conditions will be favourable. However, such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements, including, but not limited to: (1) the risk that domestic production may not be achieved as planned; (2) changes in project parameters as plans evolve; (3) dependence on regulatory approvals and changes in legislation, environmental compliance, community support and the political and economic climate; (4) availability of future financing; and (5) the timely completion of the Company’s production facility and other factors beyond the control of the Company. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements.  The Company assumes no obligation to update such information, except as may be required by law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Bedrocan Cannabis Corp.


Cam Battley, Bedrocan Cannabis Corp.

Investor relations:
Jennifer Wood,
TMX Equicom
+1.416.815.0700, ext. 226


0 262

Umbral Signs a Non-Disclosure Agreement for a process to produce Industrial Hemp in Canada

Vancouver, BC / ACCESSWIRE / February 10, 2014 / UMBRAL ENERGY CORP. (UMB.V) (OTCQB:UMBBF) (the “Company” or “Umbral”) announces, as an addition to its current activities, the Company has recently been investigating the business opportunity of Industrial Hemp. In this regard the Company is pleased to announce that it has recently signed a Non-Disclosure Agreement (“NDA”) with a group, for the purposes of producing Industrial Hemp.

This NDA allows Umbral to enter into detailed discussions with a private corporation for the production of Industrial Hemp as an additional product offering. Umbral CEO, Jag Bal states “We are continually looking at ways to develop our business, and we see great potential in this related opportunity. We feel that the infrastructure which exists in PhyeinMed, would lend itself perfectly to Industrial Hemp.”

At this time, no further deal terms have been reached, nor has the company entered into any letters of intent or definitive agreements with the private corporation. As the company’s discussions remain at a preliminary stage only, there can be no assurance or guarantee that the company will enter into a binding agreement. The company will provide further updates as they are available.

Hemp is a crop that is grown globally, principally for fibre and food. The marketable parts, include the stalk, consisting of both long (bast) and short (core) fibers, used for textiles, rope and twine, advanced composite materials, and hemp cement. The hemp seed is used, as it contains protein, dietary fiber and rich omega fatty acid oil. Hemp food products on the market today include cereal, snacks and bars, breads, milk drinks, protein powders and butter. The hemp oil is recognized as a valuable natural ingredient in body care products. The majority of hemp and hemp seed that is used in North America is grown and processed in Canada. Canada has developed its production rules from the standards developed by the European Union, and has a high regulatory standard. Canadian farmers have been legally allowed to grow industrial hemp since 1998. The Canadian Hemp Trade Alliance says production in this country is forecast to almost double by 2015.

The Company is currently listed as a junior resource issuer having a mineral exploration projects. The Company is considering other activities to increase shareholder value, including non-resource projects. The Company is conducting diligence in regards to the commercial cultivation of marijuana under the newly established Health Canada regulations pertaining to the cultivation of marijuana for medical purposes. While it is the intention of Umbral and PhyeinMed to obtain a MMPR Licence, there can be no assurances that it will receive the necessary permits to operate. Any MMPR applicant, including PhyeinMed, will not be able to legally grow or sell medical marijuana without a licence from Health Canada. In addition the Company has a mineral exploration project in Quebec, Canada as well as an oil and gas project in Alberta, Canada.


Jag Bal”

Jagdip Bal

President and CEO

Neither Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors – including the availability of funds, the results of financing efforts, the results of exploration activities — that could cause actual results to differ materially from the Company’s expectations are disclosed in the Company’s documents filed from time to time on SEDAR (see Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Umbral Energy Corp.

3 1887

The que to establish a Canadian legal marijuana business is getting unruly as applicants struggle to keep their dreams of selling med pot growing.

Written By: Matt Mernagh

This week licensed producer New Age Medical Solutions Inc. launched a lawsuit seeking a federal judge review their denial.


The business waited a year and spent approximately one million dollars Canadian before Health Canada nixed their application. The company is part of a growing list of applicants who have spent a considerable sum and are in an approval quagmire.


Many are designated growers under the old program who have teamed up with investors and require to submit to extensive RCMP background checks. Long suspecting these growers are earning income from illegal sales – the RCMP is possibly using this as an opportunity to punish via slowness.


You’ll never prove beyond a shadow of a doubt they’re not moving paperwork quick enough because of political reasons, but they’re notoriously slow on regular background checks and blame staffing levels.


Having faced numerous constitutional challenges (including my own R v. Mernagh) – the agency responsible for overseeing licensed producers appears to have established their medical marijuana program with one eye on the courtroom.

Denied applicants may re-apply by fixing the identified problem – it’s alleged by Health Canada New Age Medical Solutions needs to hire a qualified quality assurance specialist.


Who is exactly qualified to be a quality assurance specialist for cannabis?


I have a book and held a court ordered exemption to grow cannabis – does that make me qualified.


A federal judge decision on that question could be years away and in the meantime the production facility sits empty.


Currently some 1,100 businesses have applied to sell medical marijuana to approximately 10,000 people. This number is growing as more doctors appear willing to sign paperwork. (I’m registered with Peace Naturals – which is not listed on TSX).


Health Canada claims about 291 businesses are in process of approval, but when will they be approved?

There’s a fairly impressive backlog of applicants and it includes a company headed by a former prime minister (John Turner) and another by a former Ontario provincial Liberal cabinet minister (George Smitherman.)

One would think a former prime minister would have some approval sway, but it doesn’t appear to be the case.


The snail’s pace approval is most likely somewhat intentional on government’s part. Unfortunately intentional government incompetence is a challenge to measure and if you’re one of 291 about to be approved – do you risk the agency’s ire by launching a lawsuit or speaking out.


To applicants and advocates it’s obvious pot hating Conservatives have slowed down the licensed producer application process to a God Bud couchlock.


Is this government incompetent business as usual or is an extra layer of personal dislike thrown in for good measure?


The Conservatives 2012 federal budget was described as “tough times for federal civil servants” with approximately 19,000 government employees given pink slips or retired out. The federal government shrank 4.8 percent and its effects are being felt everywhere, including medical marihuana approval.


Paper is not being pushed as quickly as applicants wish, probably because Health Canada doesn’t have adequate resources. Every business that qualifies will be granted a license, but Health Canada needs to have staff in place to manage all that Conservative created paperwork and oversight.


Will positive political muscle make a difference in moving paperwork?


The Mayor of Campbellton New Brunswick has come forward seeking the approval pace be quickened for Zenabis – which has promised a remarkable 400 weed jobs – when they open in his community. Campbellton’s been hard hit by unemployment and approximately 1400 people have applied for weed employment.


Is local Conservative MP Bernard Valcourt more interested in upholding prohibition or job creation?

It’s not uncommon for an MP to lobby on behalf of a business in their community that promises job creation – so why isn’t he going to bat for Zenabis?

The Conservative’s believe they are getting a two-for-one political ideological deal – smaller government and maintaining pot prohibition – but should be viewed as hampering job creation and investment.

Investors have tied up their cash flow in an investment that may or may not pay off. Many companies’ are bleeding money before they have even opened their doors. The approval uncertainty is finally causing investors to examine the possible payout more diligently.

Cannabis conspiracy theorist need look no further than Health Canada not having enough staff as to why more companies are not retailing medical cannabis than any other theory being floated.


0 607

Canada Will Tax Marijuana Just Like Tylenol

Cannabis Investment Expert Joins Supreme Pharmaceuticals

Supreme Pharma (SL-CSE) (SPRWF-OTCBB)

Interview with Brayden R. Sutton, Executive Vice President

VANCOUVER, British Columbia, Oct. 31, 2014 (GLOBE NEWSWIRE) — Tax Court Justice Campbell Miller just ruled that marijuana will be subject to federal Goods & Services Tax (GST) like Tylenol, cough drops and other over-the-counter drugs. The ruling confirms the government’s intent to legalise, regulate and tax medical marijuana in Canada. This is an important ruling, given that recent legislative changes have created a nascent medical marijuana industry in Canada that could be valued at over $1 Billion dollars in just a few years.

The creation of this newly commercialized industry creates a great opportunity for savvy investors to be early entrants and gain substantial returns. However, there are currently dozens of publically traded companies applying for permits to grow marijuana. The challenge is to pick the winning horse. With a space this cluttered it is instructive to see where the experts are placing their bets.

Supreme Pharmaceuticals (SL.V) (SPRWF) has just landed one of those experts, Mr. Brayden R. Sutton, President and CEO of Mr. Sutton joins Supreme as one of the most prominent cannabis investment experts in Canada, with nearly a decade spent covering the field from operational and public markets perspectives. As Executive Vice President of Supreme, Mr. Sutton will oversee facility design, operations, marketing, financing and business development.

“Being an early mover in the cannabis space, I was sought after and extended offers from almost every cannabis-related company in Western Canada as they all tried to position themselves in the marketplace,” stated Sutton in an exclusive interview with Financial Press, “Some of the offers were very tempting but I was truly looking for a company that checked all the boxes — the one that is providing Health Canada precisely what they’re looking for in the MMPR, one that could provide good value to their patients as well as their shareholders, and one that I felt will be around 10 years from now. I’m not interested in being a small player in the space or making a quick buck in a new sector – I want to take Supreme, the best company in the space in my opinion, to the finish line; and really set it up to be the dominant, low-cost, high-quality producer here in Canada.”

“Supreme received its ready-to-build permit back in January of this year,” stated Sutton, “Our facility has been fully retro-fitted to exceed the requirements of the Health Canada. It’s large, it’s secure, it’s in the right area, and we have local political support — on all levels. From local MP’s, the Mayor, and the town itself. We truly couldn’t be in a better town than Kincardine, Ontario. The 16-acre property, which houses the 7-acre facility, is located on the Bruce Energy Centre and has been independently appraised with an ‘in-use’ value of just under $22 million. We were fortunate enough to secure it for only $4.5m on very favourable terms. And frankly, we’ve yet to find a facility in Canada that is as more ideally suited to the MMPR as this one is, particularly when considering the local support, available skilled labour pool and heightened law enforcement presence due to our proximity to the Bruce Nuclear Power Plant. Our final phase of security is underway as we speak with Marcomm Systems Group and our Security Director, former OPP Drug Investigator Alan Roberton. We expect them to be complete by early November, at which point we will be ready to invite Health Canada to our facility for the inspection.”

Supreme’s Southern Ontario greenhouse is state-of-the-art, high tech facility utilizing advanced agricultural automation methods and applying them to the production of medical marijuana. It’s a 342,000 square foot greenhouse, which is the size of six NFL football fields. In addition, it is perfectly designed for medical marijuana production: it is built out of mould resistant tempered glass and steel, has sealed concrete flooring and is a “low top” design which reduces the facility’s heating and cooling requirements.

“We’ve employed Thaddeus Conrad, who is one of Canada’s leading producers of medical marijuana. Mr. Conrad is a leading breeder of innovative medical marijuana varieties, varieties which have earned him the title of North America’s most awarded marijuana breeder. As a result of this, Mr. Conrad is incredibly well-known under the name ‘Med-Man Brand,'” stated Sutton. “It is an honour to have him exclusively, as he brings with him decades of practical experience as well as a large and loyal patient following for early patient acquisition out of the gate. He is now collaborating with our team of greenhouse technicians, which includes one of Canada’s top agricultural experts who is a researcher at a well-known local University. At Supreme we have three elements: in our greenhouse we acquired the ideal facility, in Mr. Conrad we retained the best medical marijuana cultivator and breeder in the country and in our agricultural team we have some of the leading experts in pharmaceutical agricultural production. By doing this, we feel we will truly have the best value in the marketplace to offer our clients top-quality medicine, consistently, at a very affordable price.”

Sutton stresses that Supreme’s facility is far from a “grow-op” – it’s a high-tech pharmaceutical-grade greenhouse that is ideally suited for medical marijuana production. Health Canada has stated numerous times that it wants a regulated, standardized, automated production system that will turn out a consistent, and most importantly, safe product that meets their very stringent quality assurance measure, and we intend to give them just that. Supreme’s facility provides that; a large volume producer, with a design and operational plan designed for standardization and safety and sufficient economies of scale to implement robust quality control and quality assurance procedures. Supreme also benefits from favourable energy rates, due to the proximity of the local power plant, and most importantly the sun, which will provide up to 60% of the energy needed to produce high-quality medical marijuana.

Supreme is quickly checking off items required to be implemented prior to inspection: the razor-wire topped security fence is in place, the level-9 vault has been installed, the growing areas have been constructed and extensive electronic security and surveillance systems are being implemented right now. Once the final security systems are in place and the production areas are finalized, Supreme will be ready for its inspection by Health Canada. Mr. Sutton states that Supreme anticipates being ready for the inspection by mid November.

“What is unique about our greenhouse is that there is a large concrete structure in the center which houses the vault and high security processing areas. The greenhouse itself provides 4 quadrants of actual growing area, 340k sq. ft. in total, with our controlled rooms being 3,520 sq. ft. each. Even the flow of the building is ideal, in terms of the steps required from the trimming of the plant, to the shipping of it out the door. Employee and product flow has been meticulously designed to increase efficiency and reduce the risk of contamination. There will be an assembly line of sorts, where the production staff will be sealed off from the rest of the operation, allowing them to move the product down the line, while not interfering with anyone who is hands on inside of the actual grow space.”

Supreme Pharma has just raised $2.6M from a recent financing and currently undertaking an additional raise. And is more than capitalized to go right into production and start fulfilling patient orders.

Through economy of scale, Sutton anticipates drastically reducing the market price of cannabis.

“Our goal is to use the extensive medical marijuana expertise our management team has to shake up the marketplace. We will achieve this by using a gradient pricing model, which allows us to target multiple market segments while maintain transparency and credibility with our patients and doctors. We will sell the majority of our products for around $5.00 per gram. From there, premium parts of each crop will be given the ‘royal treatment’ and sold for upwards of $8.00 per gram, to those who can afford it. On the other end of the spectrum, smaller buds and shake will be sold for $2 and $1 respectively. Its all good medicine, but you have to be honest with the doctors and patients about what you are providing. The low cost options are also essential because a large proportion of our patients are very cost-sensitive, and currently expend a great deal of their monthly income on their medicine. The low cost model also improves our ability to pressure insurance providers to provide benefits for medical marijuana.”

Sutton is also very focused on patient acquisition, “The part of the business that many companies are struggling to find an effective way. We are very happy to say that we have roughly 500 patients on stand-by, with many more contacting us daily.” Mr. Sutton reports these patients come from existing relationships held by Supreme’s management team, as well as many individuals living or working near the facility, “and that has all been organic so far, as we’ve not yet had to pay one dime for patients. I have some long-standing relationships with cannabis-friendly physicians, and our hope is to be able to work closely with them, to better educate the public in what is very much going to be an industry driven part of Canada’s Health Care.” This is a benefit for Supreme, as this early patient acquisition is achieved without expending capital to acquire initial patients. In addition, Mr. Sutton reports that Supreme has had strong interest from a number of potential producers to provide marijuana on a wholesale basis. “This is the perfect market opportunity for Supreme, where we can supply others with wholesale marijuana and increase our revenues faster than we can acquire our own patients. Also, when you consider that less of an expense is required to sell wholesale medical marijuana as compared to retailing to individual patients, the profitability of our wholesale division is on par with the retail side.”

“We are in the final stages of completing of the requirements for our Southern Ontario growing facility,” stated Sutton, “I have a decade of experience in this field that tells me when something is going to work. Supreme Pharmaceuticals is that something. In my opinion, it is a question of ‘when’ not ‘if’ it becomes one of the dominant providers in this exciting new sector.”

Supreme Pharmaceuticals is currently trading at $.47 with a market cap of $28 million.

Legal Disclaimer/Disclosure: A fee has been paid for the production and distribution of this Report. This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. No information in this article should be construed as individualized investment advice. A licensed financial advisor should be consulted prior to making any investment decision. Financial Press makes no guarantee, representation or warranty and accepts no responsibility or liability as to its accuracy or completeness. Expressions of opinion are those of the authors only and are subject to change without notice. Financial Press assumes no warranty, liability or guarantee for the current relevance, correctness or completeness of any information provided within this article and will not be held liable for the consequence of reliance upon any opinion or statement contained herein or any omission. Furthermore, we assume no liability for any direct or indirect loss or damage or, in particular, for lost profit, which you may incur as a result of the use and existence of the information, provided within this article.

Also, please note that republishing of this article in its entirety is permitted as long as attribution and a back link to are provided. Thank you.


Supreme Pharmaceuticals
Suite #430, 580 Hornby Street
Vancouver, BC
V6C 3B6
Phone: 604.674.2191

0 98

Surna, Inc. Announces Senior Leadership Changes

BOULDER, Colo., Feb. 26, 2015 /PRNewswire/ — Surna Inc. (SRNA), an engineering, manufacturing, and installation Company specializing in commercial indoor cannabis cultivation technology, announced today senior leadership changes reflecting its continued evolution from start-up to fast-paced manufacturing and engineering company.

Surna announced that Tom Bollich, current Director and CEO, will be stepping down on April 15th.  “I’m extremely proud of what the team has accomplished thus far and grateful I was able to add value during Surna’s start-up stage,” commented Bollich.  “Now the timing is right to transition into new leadership, and I’m confident the current team will continue to evolve Surna into the unquestioned leader in the cannabis industry. I’m excited about Surna’s future.”

Bryon Jorgenson will take over as CEO of Surna, after recently joining the Company as COO in January.  “The experience that Tom has as a entrepreneur has been invaluable. He did an outstanding job guiding Surna from startup to a substantial manufacturing company with over 30 employees and expanding revenue. I look forward to working with him during this transition period to further Surna’s technological leadership in the cannabis sector.”  Jorgenson added, “I’m very excited to drive excellence in the execution of the vision that has been formed at Surna, and look forward to leading the Surna team to a dynamic and bright future!”

Jorgenson has more than 25 years of experience at the executive-level and as an engineer in industrial electronics, life sciences, and industrial automation systems. Bryon’s career has focused on business development functions including product commercialization, pre-acquisition due diligence, business integration, management team transition, and operations performance improvement.

About Surna, Inc.:

Surna, Inc. ( develops innovative technologies and products that monitor, control or address the energy and resource intensive nature of indoor cannabis cultivation. Currently, the Company’s revenue stream is based on its main product offerings – supplying industrial technology and products to commercial indoor cannabis grow facilities.

Headquartered in Boulder, CO, Surna’s diverse engineering team is tasked with creating novel energy and resource efficient solutions, including the Company’s signature water-cooled climate control platform. The Company’s engineers continuously seek to create technology that solve the highly specific demands of the cannabis industry for temperature, humidity, light and process control.

Surna’s goal is to provide intelligent solutions to improve the quality, the control and the overall yield and efficiency of indoor cannabis cultivation. The Company’s operations exclude the production or sale of marijuana.

Safe Harbor Statement

This news release contains statements that involve expectations, plans or intentions (such as those relating to future business or financial results, new features or services, or management strategies) and other factors discussed from time to time in the Company’s Securities and Exchange Commission filings. These statements are forward-looking and are subject to risks and uncertainties, so actual results may vary materially. You can identify these forward-looking statements by words such as “may,” “should,” “expect,” “anticipate,” “believe,” “estimate,” “intend,” “plan” and other similar expressions. Our actual results, such as the Company’s ability to finance, complete and consolidate acquisition of IP, assets and operating companies, could differ materially from those anticipated in these forward-looking statements as a result of certain factors not within the control of the company such as a result of various factors, including future economic, competitive, regulatory, and market conditions. The company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. The company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

Statement About Cannabis Markets

The use, possession, cultivation, and distribution of cannabis is prohibited by federal law.  This includes medical and recreational cannabis.  Although certain states have legalized medical and recreational cannabis, companies and individuals involved in the sector are still at risk of being prosecuted by federal authorities. Further, the landscape in the cannabis industry changes rapidly.  What was the law last week is not the law today and what is the law today may not be the law next week.  This means that at any time the city, county, or state where cannabis is permitted can change the current laws and/or the federal government can supersede those laws and take prosecutorial action. Given the uncertain legal nature of the cannabis industry, it is imperative that investors understand that the cannabis industry is a high risk investment. A change in the current laws or enforcement policy can negatively affect the status and operation of our business, require additional fees, stricter operational guidelines and unanticipated shut downs.

At the Company

David Traylor
Chief Business Officer

Investor Relations

David Kugelman
Atlanta Capital Partners, LLC
+1-(866)-692-6847 Toll Free – U.S. And Canada

To view the original version on PR Newswire, visit:

0 93

InMed Pharmaceuticals, Inc. Closes Non-Brokered Private Placement for up to $1,050,000


VANCOUVER, British Columbia , Feb. 25, 2015 /CNW/ — InMed Pharmaceuticals, Inc.(“InMed”) (CSE: IN; OTCQB: IMLFF), is pleased to announce that it has closed the non-brokered private placement for 10,500,000 units (“Units”) at a price of $0.10 per Unit (the “Financing”).  Each Unit consists of one common share and one non-transferable share purchase warrant.  Each whole warrant will be exercisable by the holder to acquire one additional common share at a price of $0.13 for a period of twenty four (24) months following the closing of the financing.

Finders’ fees of 10% on a portion of the gross proceeds received by the Company from the sale of Units sold pursuant to the Financing shall include cash of ($78,550.00) and 785,500 warrants (“Agent Warrants”).   Each Agent Warrant shall be exercisable in whole or in part at an exercise price of $0.13 for a period of 24 months from the closing of the Financing.

The net proceeds from this private placement will be used for general working capital purposes. All securities issued pursuant to the Financing will be subject to a four month and one day hold period from the date of closing of the Financing.

About InMed

InMed is a clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed’s proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value drivers of the company. For more information, visit


InMed Pharmaceuticals Inc.
Craig Schneider
President and Chief Executive Officer
T: 604.669.7207
F: 604.683.2506

Tiberend Strategic Advisors, Inc.
Joshua Drumm , Ph.D. (Investors)
Amy Wheeler (Media)

Forward Looking Statements

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws.  Forward-looking information is based on management’s current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.  Forward-looking information in this news release includes statements about the use of net proceeds from the private placement and the expected fundamental value drivers of the company. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct.  Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Known risk factors include, among others: InMed may not use net proceeds received from the private placement as currently contemplated and InMed’s proprietary platform technology, product pipeline and accelerated development pathway may not return their expected level of value.

A more complete discussion of the risks and uncertainties facing InMed is disclosed in InMed’s continuous disclosure filings with Canadian securities regulatory authorities at All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.


SOURCE InMed Pharmaceuticals Inc.

View photo


0 180

United Cannabis Corporation and Cannabinoid Research & Development Enter Business Partnership with Jamaica’s Scientific Research Council and University of the West Indies, Mona, Jamaica

Initial Focus Will Be Research to Support Patent Applications and Pre-Clinical Trials for Prana Bio Medicinal Product Line

DENVER, CO / ACCESSWIRE / February 25, 2015 / United Cannabis Corporation (CNAB) (the “Company” or “United Cannabis”) today announced that it has entered into a Business Partnership with Cannabinoid Research & Development (“CRD”) and Jamaica’s Scientific Research Council, to establish a branded genetic database and conduct product analysis and preclinical studies of its entire Prana Bio Medicinal product line. The Partnership will collaborate with the University Of The West Indies, Mona (“UWI”) and have access to its staff and facilities, most notably the School of Medical Sciences, Clinical Trial Centre, and eight associated hospitals.

The announcement comes on the heels of last night’s news that Jamaica’s House of Representatives passed an amendment to its Dangerous Drugs Act, decriminalizing small amounts of marijuana and instituting a licensing agency to establish and regulate a domestic medical marijuana industry.

The changes to the Act will facilitate ganja use for therapeutic purposes, as prescribed by a registered practitioner, or for scientific research conducted by an accredited tertiary institution or otherwise approved by the Scientific Research Council (SRC). SRC is a public sector agency tasked with fostering scientific research and promoting its application within Jamaica.

Commenting on the announcement Tony Verzura, Untied Cannabis’ Chief Technical Officer, stated, “The SRC’s and UWI’s support of our vision for the creation of a state-of-the-art research and development facility is invaluable. With their support, we can now begin the preliminary safety and efficacy testing of our Prana Bio Medicinal Products. The data gathered will be used to further the patent filings we made this past October, as well as help us prepare the protocol documentation necessary to commence clinical trials.”

Mr. Verzura continued, “I see the effect our Prana products have on patients every day, and it’s not just therapeutic; it impacts their entire lives. The opportunity to verify the anecdotal evidence thru the clinical process is the moment of truth. This Partnership will enable us to provide the medical community and policymakers with clinical data to substantiate those results.”

By virtue of the Partnership, United Cannabis and CRD can begin to implement their plans to standardize the cultivation of cannabis and production of medical cannabis products for research and development. One step in this process will be the creation of a “Ganja Cooperative,” which will provide local farmers with access to established genetics as well as training in proven cultivation methodologies, in order to generate standardized crops with optimum yields. Uniform plant production is the precursor to further production, processing and testing.

John Sayers, Jamaican-based Director of CRD, went on to say “This is a very strong partnership. SRC and UWI are on the frontlines of Jamaica’s impending cannabis industry, and our relationship with them gives us the ability to begin channeling the resources we need to begin this project while the infrastructure provided for in the amendment goes into effect. This is an exciting time for the cannabis industry, and I look forward to working with this team to help establish Jamaica as a frontrunner in the innovation of cannabinoid science.

Marcus Richardson, Chief Technology Officer of CRD “The passing of this amendment makes clear that the Jamaican government recognizes the potential impact of cannabis, as a medicinal herb for the world, and an industrial product that just might be the healing of the nation. This Partnership is a first step towards scientifically exploring pure plant profiles, i.e phytocannabinoids, as medicine, and I expect the results will be significant.”

About United Cannabis Corporation

United Cannabis Corporation was founded to provide leadership for the medical cannabis industry by offering patient driven solutions intent on improving biomedical and pharmaceutical pursuits thru the use of cannabis-based research, products and services. For further information, please visit

About Cannabinoid Research & Development

Cannabinoid Research and Development Company Limited is a Jamaican-based corporation pursuing local licensing to advance the use of medical cannabis therapies through biomedical research and development for the nutraceutical industry. The company focuses on genetic restoration, cannabinoid isolation techniques, scientific research, educational programs, and promoting domestic job opportunities. The company is pioneered by Marcus Richardson, a cannabis veteran from Canada, with over 20 years of resin isolation experience, and backed by Jamaican partners specializing in agricultural science and plant-based medicine.

About Scientific Research Council

The Scientific Research Council is Jamaica’s principal public sector agency, responsible for the fostering and coordination of scientific research and the promotion of its application. Most of the Council’s projects support the growth and development of the agro-industrial sector in Jamaica through research, adaptation of available technologies, creation of new and appropriate technologies and the provision of training and technical assistance.

About the University of West Indies

UWI is the largest and longest standing higher education provider in the English-speaking Caribbean. UWI offers undergraduate and postgraduate certificate, diploma and degree options in Engineering, Humanities & Education, Law, Medical Sciences, Pure & Applied Sciences, Science and Agriculture, and Social Sciences. Its Clinical Trial Centre was established to provide the necessary support to investigators for protocol development, budgeting, ethical guidelines, data management and reporting.

Forward-Looking Statements

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933, and are subject to Rule 3B-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and other results and further events could differ materially from those anticipated in such statements. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.

Phone: 303-386-7321

SOURCE: United Cannabis Corporation

0 131

Easton Pharmaceuticals Discloses Existing Medicated Market Revenues From Its Medical Marijuana Operations That Have Surpassed $2,000,000; Provides Clarification on Other Items

HUMBOLDT, CA–(Marketwired – Feb 24, 2015) – Easton Pharmaceuticals Inc (OTC PINK: EAPH) discloses existing Medicated Markets Revenues from medical marijuana operations totaling more than $2,000,000 in fiscal 2014; provides clarification on other items.

Easton Pharmaceuticals has been provided with revenue numbers from Medicated Markets from its medical marijuana operations in California for 2014, revealing revenues that have surpassed $2,000,000. These sales numbers relate to the past year and are derived mainly from sales to dispensaries as shown in past invoices @medimarkets. The invoices exhibited are just a sample, and as such do not represent all sales made.

Responding to many similar type questions posed, Medicated Markets does not sell direct to patients and has no retail locations. Total harvested marijuana is sold on a wholesale level to licensed dispensaries in the greater Los Angeles region. These dispensaries are open to marijuana prescription holders only.

Operations are expected to be ramped up following anticipated investments to infrastructure, which are to be derived from proceeds from its transaction with Easton pharmaceuticals and other possible investment options and sources. With infrastructure upgrades, Medicated Markets can increase the number of plants grown from the current number of 1200, to 10,000 plants, which are tiered to harvest on a weekly basis following a 70-100 day variable cycle based on strain. 2014 yield from plants were approximately 1500 lbs. In 2014 medicated markets donated approximately 10% of its production to financially strained patients on a compassionate basis.

As previously disclosed, Medicated Markets projected $32,000,000 in potential sales for fiscal 2015 if many conditions were met including optimal selling and growing conditions including yields from additional purchased property. Please note this figure is based on January 2015 pricing. Prices have ranged from $1350 to $2000 per pound in 2014 and can significantly affect sales and profits and as such amended revenue range is provided below.

In January of 2015, prices had spiked to $2185 increased for medicinal marijuana In California, which was the estimate used to derive sales numbers. Using adjusted conservative numbers of only 1 pound per plant as a yield and $1350 which was the lowest price sold for in 2014 after upgrades to property, Medicated Markets would yield $13.5 million for 2015 or $3.37 million quarterly. If a conservative SG&A of 30% were used, it would result in a profit of $2.359 Million of which Easton would be allocated 40% ownership or $943,000 per quarter. This is nearly a 100% Return on equity paid for in restricted shares in 1 year of operation.

Medicated Markets were provided an initial upfront cash payment and issued “rule 144 restricted shares” (which are in escrow till maturity) and not free trading shares. These shares were valued at .02 giving the transaction a value of $4,000,000.

Many have noted negative trading activity in Easton pharmaceutical stock in the month of February. We believe it is Marijuana sector related and highly influenced by certain happenings with another sector related company ( FITX ).

Questions relating to Medicated Markets Operations should be sent or

In other news, previous investments made by Easton Pharmaceuticals towards its OTC therapeutic products have now resulted in having its 3 products completed and ready for marketing and sale. News on its finalized distributorship agreement and payments made towards attending a leading health show will soon result in the announcement of product launch which was unfortunately made much later than initially planned due to changes in Mexico manufacturing and with the main focus of the company having been transferred to its medical marijuana initiatives. In addition, news stemming from progress on its Canadian medical marijuana ventures and announcements on its AMFIL investment is to be soon provided.

About Easton Pharmaceuticals
Easton Pharmaceuticals is a specialty pharmaceutical company involved in various pharmaceutical sectors and others industries such as medical marijuana. The Company previously developed and owned an FDA approved wound healing drug and currently owns topically-delivered drugs and other therapeutic products that are all in various stages of development. Easton has completed an acquisition that grants 40% ownership interest in Medicated Markets International LLC assets; a California Licensed Medical Marijuana Grower on 20 acres (3 acre growing area). Easton has also made additional investments into AMFIL Technologies and their groZONE anti-microbial airflow system needed for growing pesticide free medicine, and have an exclusive option to purchase up to 49% in a medical marijuana grow-op business post granting of license from Health Canada in Port Perry, Ontario, which has received a letter to build from Health Canada. The company’s gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of Cannabidiol extracts.

For More Information Visit:

Safe Harbor
This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The “Act”). In particular, when certain words or phrases such as “hope,” “positive,” “anticipate,” “pleased,” “plan,” “confident that,” “believe,” “expect,” “possible” or “intent to” and similar conditional expressions are expressed, they are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals would be classified as speculative and may contain risks. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company’s products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company’s financial reports and filings.

Carla Pepe
Tel: +1(416) 619-0291
Tel: +1(347) 284-0192

0 100

Lexaria Letter From the President

 Kelowna, BC / ACCESSWIRE / February 24, 2015 / Lexaria Corp. (LXRP) (CSE:LXX) (the “Company”) is pleased to provide a Letter From the President for all its stakeholders.

Lexaria has posted at its website a letter from the president, outlining recent corporate activity and current and future business plans. The complete Letter from the President is also being filed with regulators in the USA and Canada, and sent directly to shareholders. A summary and excerpt from the letter follows.

I am pleased to offer this update on Lexaria Corp to all stakeholders, following many changes in the Company during the past year.

It is a particularly exciting time in the Company’s history. 2014 delivered the sharpest and most severe decline in oil prices in over 5 years, and one of the biggest declines of all time. In 2012 we quietly initiated efforts to maximize value from our Belmont Lake oil field through any means possible, including a complete asset sale.

The oil field was sold late in 2014. At a peak, we owed over $1.7 million to various creditors, much of this to management and directors who had provided significant loans to enable our operations. We are proud to have paid all these loans down to a zero balance and that every creditor was paid in full.

At our annual general meeting in 2014, you responded overwhelmingly in favor of our entry into the medical marijuana sector, and we have responded with vigor. We now have a joint venture that has applied to Health Canada, the governing body of the medical marijuana industry in Canada, for a license to produce 10,000 kg (approx 22,000 pounds) of medical marijuana per year. Lexaria owns 49% of that joint venture.

Meanwhile, we don’t want to either bet the entire company on a single license application; or ignore the much larger market for already-legal agricultural hemp products. It’s important to clearly understand our foray into the United States market: In the USA we do not sell cannabis and are not involved in the marijuana trade in any way, even in those states where it is legal to do so under state law.

We are proud to help people in their quest for health and wellness, and we have come to believe that CBD may play an integral role in general good health. As a publicly traded company we believe this is not only the more prudent path for our company to take on behalf of its investors, but also the more profitable one.

Having unveiled our website and upon selling our first cup of tea, we became a national company able to sell our CBD infused tea – using patent-pending technology – anywhere in the United States.

In order to attempt to generate sales revenue, and with them, our expectations of eventual profits, we purchased 51% of PoViva Tea LLC and launched the ViPova(TM) brand of Cannabidiol (CBD) infused teas. Of all the steps we’ve taken in guiding Lexaria forward over recent years, we are perhaps most excited about our entry into the CBD business. Lexaria is playing a leading role in this brand new industry by delivering CBD through our unique and distinctive lipid-infused process making it one of the most exciting emerging companies in the business today.

2015 will be a very busy year for us – we have a number of goals and initiatives.

Primary among these is to establish ViPova(TM) as a widely recognized and trusted brand for delivering CBD using our patent pending process that we believe is more effective and comforting. As brand recognition grows we intend to broaden the brand with other products, such as flavored teas and coffee. ViPova(TM) sales and product introductions will constantly be a focus during 2015.

We will also launch our second brand of products under the Lexaria Energy brand, keeping a smile on our corporate face as we use our original name for new purposes. Lexaria Energy will be launched in the first 6 months of 2015 as a line of nutritional supplements for active people, once again always using our patent pending technology to infuse CBD inside for comfort and effectiveness.

We expect our first product to be a CBD/Protein bar of exceptional quality and taste. We are hoping to make the Lexaria Energy Bar the only bar in the world that is low on the glycemic index; gluten-free; and incorporates CBD with our patent-pending technology. It is currently under development.

2014/2015 is a period of change for your company. We know we made the right move to back away from the oil and gas business, and the economics in that business have deteriorated even more rapidly than we feared they might. We have paid all our bills and debts so that the Company is not burdened or placed at risk. We’ve entered the medical marijuana business through a license application in Canada. And we are launching two new brands in the USA aimed at the exciting brand new fields of cannabidiol delivery.

Though there has been a lot of change, one thing in particular remains constant: our thanks to you our shareholders for your loyalty and steadfastness over the years. It is hard being a mouse among elephants but we’ve tried our best to work hard for you all the while we avoid being stepped on. Our commitment to you remains unchanged and we will work honestly and tirelessly on your behalf.


Chris Bunka
President and CEO, Lexaria Corp.

About Lexaria

Lexaria’s shares are quoted in the USA with symbol LXRP and in Canada with symbol LXX. The company searches for projects that could provide potential above-market

About ViPova(TM)

ViPova(TM) uses only legal CBD oil extracts, grown from legal hemp in locations where it is legal to do so, in ViPova(TM)-branded tea. ViPova(TM) uses its patent-pending process to infuse concentrated amounts of CBD within lipids in its tea, providing more bioactivity and comfort to the body during the absorption process. Only ViPova(TM) has this ground-breaking technology for CBD/lipid infusion.


Lexaria Corp.
Chris Bunka
Chairman & CEO
(250) 765-6424


This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Access to capital, or lack thereof, is a major risk and there is no assurance that the Company will be able to raise required working capital. Current oil and gas production rates may not be sustainable and targeted production rates may not occur. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that the medical marijuana, CBD sector, or alternative health businesses will provide any benefit to Lexaria, or that the Company will experience any growth through participation in these sectors. There is no assurance that existing capital is sufficient for the Company’s needs or that it will need to attempt to raise additional capital. There is no assurance that any planned corporate activity, business venture, or initiative will be pursued, or if pursued, will be successful. There is no assurance that any cannabinoid-based product will promote, assist, or maintain any beneficial human health conditions whatsoever. No statement herein has been evaluated by the Food and Drug Administration (FDA). ViPova(TM) products are not intended to diagnose, treat, cure or prevent any disease.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

SOURCE: Lexaria Corp.

0 115

Canadian Securities Regulators’ Review Finds Medical Marijuana Business Disclosure Deficient

TORONTO , Feb. 23, 2015 /CNW/ – Members of the Canadian Securities Administrators (CSA) today released CSA Staff Notice 51-342 Staff Review of Issuers Entering Into Medical Marijuana Business Opportunities, which summarizes the CSA’s findings and disclosure expectations for reporting issuers contemplating involvement in Canada’s medical marijuana industry.

The CSA’s review aimed to determine if reporting issuers were meeting the requirements of National Instrument 51-102 Continuous Disclosure Obligations, in providing sufficient and balanced disclosure on their intent to enter the medical marijuana field.

“Overall, the review found unbalanced and promotional disclosure that often promoted the benefits, but failed to outline the risks involved,” said Bill Rice , Chair of the CSA and Chair and CEO of the Alberta Securities Commission. “The level of deficiency in issuers’ disclosure is unacceptable as investors need comprehensive, balanced information to understand the business changes being proposed by these issuers.”

While the review found that the benefits associated with involvement in the medical marijuana industry were often discussed, these discussions were not consistently accompanied by clear disclosure about the risks, cost and time required before an issuer can begin licensed operations. Additionally, issuers’ disclosure often did not include a discussion about the barriers and obligations to entering this industry.

The CSA determined that 25 reporting issuers raised serious investor protection concerns. These reporting issuers were generally at a preliminary stage of entry into the medical marijuana field.

The CSA sent comment letters to all issuers in the scope of its review and asked 92 per cent of them to file a clarifying disclosure document, which they did.

The review identified, among others, the following disclosure deficiencies:

  • lack of clear discussion regarding the issuer’s stage of entry into the medical marijuana field;
  • no discussion about time and cost requirements;
  • lack of discussion regarding Health Canada’s medical marijuana licensing requirements;
  • failure to acknowledge that the issuer will not be able to grow or sell medical marijuana without a licence from Health Canada; and
  • no discussion of approvals obtained or required before the issuer may proceed with its proposed business plans (for example, from the board of directors, shareholders or the issuer’s securities exchange).

The CSA will continue to review announcements from issuers exploring medical marijuana opportunities through its continuous disclosure and prospectus review programs. Issuers should also note that the disclosure guidance in this notice is applicable to companies in any industry considering a change to their primary business.      

CSA Staff Notice 51-342 is available on CSA members’ websites.

The CSA, the council of the securities regulators of Canada’s provinces and territories, co-ordinates and harmonizes regulation for Canadian capital markets.

SOURCE Canadian Securities Administrators

View photo


Carolyn Shaw-Rimmington, Ontario Securities Commission, 416-593-2361; Mark Dickey, Alberta Securities Commission, 403-297-4481; Richard Gilhooley, British Columbia Securities Commission, 604-899-6713; Sylvain Théberge, Autorité des marchés financiers, 514-940-2176; Kevan Hannah, Manitoba Securities Commission, 204-945-1513; Andrew Nicholson, Financial and Consumer Services, Commission, New Brunswick, 506-658-3021; Tanya Wiltshire, Nova Scotia Securities Commission, 902-424-8586; Janice Callbeck, Office of the Superintendent of Securities, P.E.I., 902-368-6288; Don Boyles, Office of the Superintendent of Securities, Newfoundland and Labrador, 709-729-4501; Rhonda Horte, Office of the Yukon Superintendent of, Securities, 867-667-5466; Louis Arki, Nunavut Securities Office, 867-975-6587; Gary MacDougall, Northwest Territories, Securities Office, 867-920-3318; Shannon McMillan, Financial and Consumer Affairs, Authority of Saskatchewan, 306-798-4160